Gene

Identification (biology)

Cancer

Cas9

Genome

Economics

Genomics

Prioritization

Drug

Cancer cell lines

Computer science

Management science

Genetics

Botany

Bioinformatics

Drug development

Computational biology

Drug discovery

Biology

Cancer cell

CRISPR

Pharmacology

Nature

Functional genomics approaches can overcome limitations-such as the lack of identification of robust targets and poor clinical efficacy-that hamper cancer drug development. Here we performed genome-scale CRISPR-Cas9 screens in 324 human cancer cell lines from 30 cancer types and developed a data-driven framework to prioritize candidates for cancer therapeutics. We integrated cell fitness effects with genomic biomarkers and target tractability for drug development to systematically prioritize new targets in defined tissues and genotypes. We verified one of our most promising dependencies, the Werner syndrome ATP-dependent helicase, as a synthetic lethal target in tumours from multiple cancer types with microsatellite instability. Our analysis provides a resource of cancer dependencies, generates a framework to prioritize cancer drug targets and suggests specific new targets. The principles described in this study can inform the initial stages of drug development by contributing to a new, diverse and more effective portfolio of cancer drug targets.

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens